Cantor Fitzgerald maintains Vertex stock at Overweight, $480 target
Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ ...
Lam upgraded to Overweight at Cantor Fitzgerald, says ‘too good to wait’
Cantor Fitzgerald upgraded Lam Research (LRCX) to Overweight from Neutral with a price target of $100, up from $95. The firm had suggested ...
Cantor Fitzgerald Boosts Earnings Estimates for Zscaler
Stock analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for Zscaler in a report released on ...
KLA Corporation (KLAC) Faces Short-Term Headwinds in Semiconductor Equipment Market, Cantor Fitzgerald Sees Recovery in 2025
Investment firm Cantor Fitzgerald recently penned a research ... Shares were likely range-bound into DOC/BIS announcement, ...
Tesla price target raised to $425 from $365 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Tesla (TSLA) to $425 from $365 and keeps a Neutral rating on the shares. Tesla’s adjusted ...